Eli Lilly, a major U.S. pharmaceutical firm, has taken an aggressive step in the growing weight-loss drug market. The company has sharply reduced the out-of-pocket cost of its popular medication, Zepbound. Through its direct-to-consumer platform, LillyDirect, the drug is now available for as low as $299 per month. The move signals a significant escalation in competition with Danish rival Novo Nordisk and could have implications for Eli Lilly’s profit margins.
The company lowered the price of Zepbound’s 2.5-milligram dose to $299 from $349. The 5-milligram dose now costs $399, roughly 20% less than before. Zepbound contains tirzepatide, a medication designed to aid weight loss in patients struggling with obesity. Lilly’s decision follows recent price adjustments by Novo Nordisk for its competing medications, Wegovy and Ozempic. Analysts suggest that Eli Lilly aims to capture a larger share of the self-pay market before Medicare expands coverage for obesity treatments in the coming years.
Market Response and Analyst Outlook
The stock market’s initial reaction was cautious. Shares of Eli Lilly experienced slight pressure as investors assessed the potential impact on profits. Despite this, many financial analysts remain optimistic about the company’s prospects.
BMO Capital reaffirmed its “Outperform” rating on Eli Lilly stock, setting a target price of $1,100. The firm argues that higher sales volumes, driven by more affordable access, could offset revenue lost to lower prices. Bernstein also maintains a positive outlook. The company points to Eli Lilly’s robust drug pipeline and sets a price target of $1,300. Currently, Eli Lilly’s stock is trading close to its all-time high of $1,111.99, reached in late November. On November 21, the company became the first healthcare firm to reach a market capitalization of more than one trillion dollars, marking a historic milestone.
Political Pressure and Strategic Timing
Eli Lilly’s pricing move comes amid political pressure on drug manufacturers to reduce costs. The Trump administration’s “TrumpRx” initiative encourages companies to lower prices in exchange for avoiding potential new tariffs or tighter regulations. The White House has announced that discounts of up to 71% for Medicare patients will take effect by 2027. By cutting prices for self-paying customers ahead of these changes, Eli Lilly positions itself competitively while navigating the evolving political landscape.
Analysts estimate that the global market for obesity treatments could reach $100 billion by 2030. Millions of patients currently cannot afford these medications. Eli Lilly’s strategy targets this large, underserved population, hoping that wider access will drive sales growth. By reducing prices, the company seeks to strengthen its position in the rapidly expanding weight-loss drug market while setting the stage for long-term profitability.
Related topics
